Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on July 14, 2008, reporting events occurring on June 20, 2008. The Company is a Florida corporation headquartered in Monmouth Junction, NJ, currently engaged in restructuring its debt obligations following multiple covenant breaches and events of default.
Key Financial Metrics and Obligations
- Outstanding Debt: The Company owes approximately $2,225,500 in principal to debenture holders, plus accrued interest and penalties.
- Specific Default Notice: A holder of a $55,000 principal 6% convertible debenture issued a notice of default and conversion.
- Conversion Terms: The holder requested conversion of 130% of the principal ($71,500) plus $22,141 in interest and liquidated damages into 187,282 shares of common stock at $0.50 per share.
- Default Interest Rate: Interest accrues at 18% per year upon default.
- Liquidated Damages: Up to 24% of the original debenture amount is due as liquidated damages for failure to register shares.
- Liquidity/Cash Flow: The filing does not provide specific cash flow, revenue, or liquidity figures.
Material Changes and Events
The Company received a notice of default citing three specific failures: removal of stock from OTCBB quotation, failure to file a registration statement for convertible shares, and failure to pay interest when due. Consequently, the full purchase amount of the debentures became immediately payable. The Company is currently negotiating Forbearance Agreements with the majority of debenture holders to avoid immediate liquidation or forced conversion.
Outlook, Risks, and Management Commentary
Management believes that failing to negotiate a satisfactory Forbearance Agreement with some or all debenture holders could have a material adverse effect on the Company. The filing includes forward-looking statements regarding the potential consequences of these defaults, noting that actual outcomes may differ materially due to risks such as adverse court determinations or regulatory changes. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the current status of the Forbearance Agreements with debenture holders.
- Confirm the total number of shares issued or reserved for conversion following the June 20, 2008 notice.
- Check the Company's current listing status on the OTCBB or other exchanges.
- Review subsequent filings for updates on the $2.2 million+ debt restructuring efforts.
- Assess the dilution impact of converting $71,500 plus damages into 187,282 shares.